Tesamorelin + Ipamorelin (Combo)
Growth Hormone Secretagogue CombinationclinicalAlso known as: Tesa-Ipa, Tesamorelin/Ipamorelin Blend, GHRH + GHRP Combo
A synergistic combination of tesamorelin (GHRH analogue) and ipamorelin (selective GHRP) that amplifies growth hormone release through dual-pathway stimulation, widely considered the gold standard GH peptide stack.
Overview
The tesamorelin + ipamorelin combination represents one of the most popular and effective growth hormone optimization protocols in peptide therapy. Tesamorelin is an FDA-approved GHRH analogue that stimulates the pituitary to produce and release growth hormone through the GHRH receptor. Ipamorelin is a highly selective growth hormone releasing peptide (GHRP) that acts through the ghrelin receptor. When combined, these two peptides create a synergistic amplification of GH release — tesamorelin primes the pituitary while ipamorelin triggers the release pulse. This combination produces GH elevations significantly greater than either peptide alone, while maintaining a clean side effect profile. The combo has become a staple in anti-aging clinics, TRT clinics, and wellness practices as a safer alternative to exogenous growth hormone.
Mechanism of Action
Tesamorelin binds to GHRH receptors on pituitary somatotrophs, increasing intracellular cAMP and priming GH synthesis and release. Ipamorelin binds to GHS-R1a (ghrelin) receptors on the same cells through a separate signaling pathway involving IP3/DAG. The dual stimulation creates a synergistic effect: GHRH opens the 'gate' while the GHRP provides the 'push,' resulting in a larger, more robust GH pulse than either agent alone. Importantly, this combination preserves the natural pulsatile pattern of GH release and maintains negative feedback regulation, unlike exogenous GH which provides flat, supraphysiological levels.
Molecular Formula
Combination product
Molecular Weight
Tesamorelin: 5135.9 g/mol; Ipamorelin: 711.85 g/mol
Sequence
Combination: Tesamorelin (trans-3-hexenoic acid-modified hGHRF(1-44)-NH2) + Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2)
Dosage Protocols
Dose Range
Tesa 1mg + Ipa 200mcg – Tesa 2mg + Ipa 300mcg
Frequency
Once daily before bed
Route
subcutaneous
Cycle Length
12-24 weeks (with periodic breaks)
Inject on empty stomach (no food for 2-3 hours before). Bedtime administration synergizes with natural nocturnal GH pulse. Some protocols use twice daily (morning and bedtime).
Source: Anti-aging clinic protocols
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
Combination vial
Last Updated
2026-02
Premium GH-releasing combo. Telehealth: $250-500/mo. Popular in anti-aging clinics. Tesamorelin adds lipodystrophy benefits.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Water retention | mild |
| Tingling/numbness in hands | mild |
| Injection site reaction | mild |
| Headache | mild |
| Joint pain | mild |
| Increased hunger | mild |
Pros & Cons
Synergistic GH release far exceeding either peptide alone — considered the optimal GHRH/GHRP pairing
Maintains natural pulsatile GH pattern unlike exogenous HGH
Ipamorelin is the cleanest GHRP — minimal cortisol, prolactin, or appetite side effects
Tesamorelin is FDA-approved with established safety data
Significant improvements in body composition, sleep quality, skin, and recovery
Requires daily injections — no oral option available
Expensive compared to single-peptide protocols
The combination is not FDA-approved; off-label use only
Results take 4-8 weeks to become noticeable
Research Studies
🩸 Blood Work
IGF-1
Combined GHRH+GHRP — potent GH elevation requires monitoring
Fasting Blood Glucose
Monitor glucose with sustained GH elevation
Fasting Insulin
Monitor insulin sensitivity
HbA1c
Long-term glucose monitoring
Liver Function Panel (AST/ALT)
Tesamorelin component — liver monitoring standard
Popular clinic-prescribed combination. Tesamorelin (GHRH) + Ipamorelin (GHRP) synergy produces robust GH response. Clinics typically require bloodwork before and during therapy.
Legal Status
Tesamorelin is FDA-approved (Egrifta) for HIV lipodystrophy. Ipamorelin is a research peptide. The combination is prescribed off-label by anti-aging and wellness clinics. Not FDA-approved as a combination product.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.